<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1130-6343</journal-id>
<journal-title><![CDATA[Farmacia Hospitalaria]]></journal-title>
<abbrev-journal-title><![CDATA[Farm Hosp.]]></abbrev-journal-title>
<issn>1130-6343</issn>
<publisher>
<publisher-name><![CDATA[Grupo Aula Médica]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1130-63432019000500003</article-id>
<article-id pub-id-type="doi">10.7399/fh.11170</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[OTAC: Optimization of Antibiotic Therapy in Critically ill Patients. Using beta-lactam antibiotics by continuous infusion]]></article-title>
<article-title xml:lang="es"><![CDATA[OTAC: Optimización de la Terapia Antibiótica en el paciente Crítico. Antibióticos betalactámicos en perfusión continua]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Esteve-Pitarch]]></surname>
<given-names><![CDATA[Erika]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Padullés-Zamora]]></surname>
<given-names><![CDATA[Ariadna]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Maisterra-Santos]]></surname>
<given-names><![CDATA[Kristel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Colom-Codina]]></surname>
<given-names><![CDATA[Helena]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
<xref ref-type="aff" rid="Ab"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cobo-Sacristán]]></surname>
<given-names><![CDATA[Sara]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto de Investigación Biomédica de Bellvitg Hospital Universitari de Bellvitge Servicio de Farmacia]]></institution>
<addr-line><![CDATA[Hospitalet de Llobregat Barcelona]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto de Investigación Biomédica de Bellvitg Hospital Universitari de Bellvitge Servicio de Medicina intensiva]]></institution>
<addr-line><![CDATA[Hospitalet de Llobregat Barcelona]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad de Barcelona Facultad de Farmacia Departamento de Farmacia y Tecnología Farmacéutica]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="A3b">
<institution><![CDATA[,Instituto de Investigación Biomédica de Bellvitg Hospital Universitari de Bellvitge ]]></institution>
<addr-line><![CDATA[L&#8217;Hospitalet de Llobregat ]]></addr-line>
<country>Spain</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>10</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>10</month>
<year>2019</year>
</pub-date>
<volume>43</volume>
<numero>5</numero>
<fpage>151</fpage>
<lpage>157</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1130-63432019000500003&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1130-63432019000500003&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1130-63432019000500003&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Objective To determine the percentage of patients given standard doses of piperacillin/tazobactam or meropenem by continuous infusion who achieved the target pharmacokinetic/pharmacodynamic (PK/PD) index, which was defined as free concentrations four times more than the minimum inhibitory concentration (CMI) for 100% of the dosing interval (100% fT&#8805; 4 x MIC).  Method Preliminary data from a larger prospective clinical study analysing the PK/PD behaviour of &#946;-lactams antibiotics continuous infusion (CI) in critical patients. The study was conducted in the intensive care units of a tertiary university hospital for adults (June 2015-May 2017). Inclusion criteria: normal renal function (glomerular renal function (GFR) CKD-EPI formula &#8805; 60 mL/min/1.73 m2) and treatment with standard dose &#946;-lactams CI. Concentrations at steady state (Css) conditions were determined using UHPLC-MS/MS. We selected the highest susceptible MIC for all likely organisms according to European Commitee on Antimicrobial Susceptibility Testing&#8217;s (i.e. piperacillin/tazobactam: 8 mg/L for enterobacteriaceae and 16 mg/L for Pseudomonas aeruginosa; meropenem: 2 mg/L for any microorganism). In addition, a subanalysis of patients was conducted using actual MIC values.  Results 61 patients were enrolled (25 to meropenem and 36 to pipe-racillin/tazobactam). Average age was 59 (15) years and median GFR rate was 95 mL/min/1.73 m2 (83-115). Median meropenem and pipe-racillin free concentrations were 16 mg/L (11-29) and 40 mg/L (21-51), respectively. 88% of patients treated with meropenem reached the PK/PD target, without differences between both microorganisms. For piperacillin/tazobactam, 61% and 11% of patients reached the target, with enterobacteria-ceae and Pseudomonas as suspected microorganisms, respectively. The pathogen was isolated in 35 (57%) patients: 94% reached the target PK/ PD, without differences between both antibiotic therapies.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivo Determinar el porcentaje de pacientes, a los que se les administró dosis estándar de piperacilina/tazobactam o meropenem en perfusión continua, que alcanzaban el índice farmacocinético/farmacodinámico diana definido como el 100% del intervalo de administración en que las concentraciones de antibiótico libre fueron cuatro veces iguales o superiores a la concentración mínima inhibitoria (100% fT&#8805; 4 x CMI).  Método Datos preliminares obtenidos de un estudio clínico prospectivo que analiza el comportamiento farmacocinético/farmacodinámico de los antibióticos betalactámicos administrados en perfusión continua en pacientes críticos. Se realizó en unidades de cuidados intensivos de un hospital universitario de tercer nivel, desde junio de 2015 a mayo de 2017. Criterios de inclusión: adultos con función renal correcta (filtrado glomerular según la fórmula CKD-EPI &#8805; 60 ml/min/1,73 m2) y tratados con dosis estándar de antibióticos betalactámicos en perfusión continua. Las concentraciones en estado de equilibrio estacionario fueron determinadas mediante cromatografía líquida acoplada a espectrometría de masas (UHPLC-MS/MS). Se utilizaron valores de concentración mínima inhibitoria teóricos para microorganismos más resistentes (piperacilina/ tazobactam: 16 mg/l para Pseudomonas aeruginosa y 8 mg/l para Enterobacteriaceae; meropenem: 2 mg/l, independientemente del microorganismo). Además, se realizó un subanálisis de los pacientes con aislamiento microbiológico (concentraciones mínimas inhibitorias reales).  Resultados Se incluyeron 61 pacientes (25 meropenem y 36 piperacilina/tazobactam). Edad media 59 años (15), mediana de filtrado glomerular 95 ml/min/1,73 m2 (83-115). Mediana de concentraciones en estado de equilibrio estacionario libre: 16 mg/l (11-29) meropenem y 40 mg/l (21-51) piperacilina. El 88% de los pacientes tratados con meropenem alcanzaron el objetivo farmacocinético/farmacodinámico, sin diferencias entre Enterobacteriaceae y Pseudomonas. En el caso de piperacilina/tazobactam, el 61% y el 11% de los pacientes alcanzaron la diana, considerando Enterobacteriaceae y Pseudomonas como microorganismo sospechoso. Un total de 35 (57%) pacientes presentaron aislamiento microbiológico. El 94% de ellos alcanzaron la diana, sin diferencias entre los dos antibióticos.  Conclusiones Ante la sospecha de infecciones por microorganismos con concentraciones mínimas inhibitorias elevadas (Pseudomonas aeruginosa o enterobacterias), se observa que dosis convencionales de meropenem en perfusión continua son suficientes para lograr la diana 100% fT&#8805; 4 x MIC. Sin embargo, se requerirían dosis superiores de piperacilina/tazobactam. En casos de aislamiento microbiológico, dosis estándar de ambos antibióticos fueron suficientes para lograr la diana. La monitorización farmacocinética es altamente recomendable para la optimización terapéutica.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Beta-lactams]]></kwd>
<kwd lng="en"><![CDATA[Critical care]]></kwd>
<kwd lng="en"><![CDATA[Pharmacokinetics]]></kwd>
<kwd lng="en"><![CDATA[Drug monitoring]]></kwd>
<kwd lng="en"><![CDATA[Piperacillin]]></kwd>
<kwd lng="en"><![CDATA[Meropenem]]></kwd>
<kwd lng="es"><![CDATA[Betalactámicos]]></kwd>
<kwd lng="es"><![CDATA[Cuidados intensivos]]></kwd>
<kwd lng="es"><![CDATA[Farmacocinética]]></kwd>
<kwd lng="es"><![CDATA[Monitorización de fármacos]]></kwd>
<kwd lng="es"><![CDATA[Piperacilina]]></kwd>
<kwd lng="es"><![CDATA[Meropenem]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Angus]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
<name>
<surname><![CDATA[Poll]]></surname>
<given-names><![CDATA[T Van der]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Severe sepsis and septic shock]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2013</year>
<volume>369</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>840-51</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rhodes]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Evans]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
<name>
<surname><![CDATA[Alhazzani]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Levy]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Antonelli]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrer]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016]]></article-title>
<source><![CDATA[Intensive Care Med]]></source>
<year>2017</year>
<volume>43</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>304-77</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Roberts]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Abdul-Aziz]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[Lipman]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Mouton]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
<name>
<surname><![CDATA[Vinks]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Felton]]></surname>
<given-names><![CDATA[TW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions]]></article-title>
<source><![CDATA[Lancet Infect Dis]]></source>
<year>2014</year>
<volume>14</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>498-509</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="book">
<collab>Grupo de trabajo de enfermedades infecciosas y sepsis</collab>
<source><![CDATA[Estudio nacional de vigilancia de infección nosocomial en servicios de medicina intensiva (EVIN-HELICS). Informe 2017]]></source>
<year>2017</year>
<publisher-loc><![CDATA[Barcelona, España ]]></publisher-loc>
<publisher-name><![CDATA[Sociedad Española de Medicina Intensiva y Unidades Coronarias (SEMICYUC)]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Roberts]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Lipman]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacokinetic issues for antibiotics in the critically ill patient]]></article-title>
<source><![CDATA[Crit Care Med]]></source>
<year>2009</year>
<volume>37</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>840-51</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Roberts]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Paul]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
<name>
<surname><![CDATA[Akova]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bassetti]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[De Waele]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Dimopoulos]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current &#946;-Lactam Antibiotic Doses Sufficient for Critically Ill Patients?]]></article-title>
<source><![CDATA[Clin Infect Dis]]></source>
<year>2014</year>
<volume>58</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1072-83</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Roberts]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Ulldemolins]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Roberts]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[McWhinney]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Ungerer]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Paterson]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Therapeutic drug monitoring of &#946;-lactams in critically ill patients: proof of concept]]></article-title>
<source><![CDATA[Int J Antimicrob Agents]]></source>
<year>2010</year>
<volume>36</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>332-9</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Delattre]]></surname>
<given-names><![CDATA[IK]]></given-names>
</name>
<name>
<surname><![CDATA[Taccone]]></surname>
<given-names><![CDATA[FS]]></given-names>
</name>
<name>
<surname><![CDATA[Jacobs]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Hites]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Dugernier]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Spapen]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Optimizing &#946;-lactams treatment in critically-ill patients using pharmacokinetics/pharmacodynamics targets: are first conventional doses effective?]]></article-title>
<source><![CDATA[Expert Rev Anti Infect Ther]]></source>
<year>2017</year>
<volume>15</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>677-88</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dulhunty]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Roberts]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Davis]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Webb]]></surname>
<given-names><![CDATA[SAR]]></given-names>
</name>
<name>
<surname><![CDATA[Bellomo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Gomersall]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Continuous Infusion of Beta-Lactam Antibiotics in Severe Sepsis: A Multicenter Double-Blind, Randomized Controlled Trial]]></article-title>
<source><![CDATA[Clin Infect Dis]]></source>
<year>2013</year>
<volume>56</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>236-44</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abdul-Aziz]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[Dulhunty]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Bellomo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Lipman]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Roberts]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Continuous betalactam infusion in critically ill patients: the clinical evidence]]></article-title>
<source><![CDATA[Ann Intensive Care]]></source>
<year>2012</year>
<volume>2</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>37</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abdul-Aziz]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[Lipman]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Mouton]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
<name>
<surname><![CDATA[Hope]]></surname>
<given-names><![CDATA[WW]]></given-names>
</name>
<name>
<surname><![CDATA[Roberts]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Applying Pharmacokinetic/Pharmacodynamic Principles in Critically Ill Patients: Optimizing Efficacy and Reducing Resistance Development]]></article-title>
<source><![CDATA[Semin Respir Crit Care Med]]></source>
<year>2015</year>
<volume>36</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>136-53</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rhodes]]></surname>
<given-names><![CDATA[NJ]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[O&#8217;Donnell]]></surname>
<given-names><![CDATA[JN]]></given-names>
</name>
<name>
<surname><![CDATA[Dulhunty]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Abdul-Aziz]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[Berko]]></surname>
<given-names><![CDATA[PY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prolonged Infusion Piperacillin-Tazobactam Decreases Mortality and Improves Outcomes in Severely Ill Patients]]></article-title>
<source><![CDATA[Crit Care Med]]></source>
<year>2018</year>
<volume>46</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>236-43</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dhaese]]></surname>
<given-names><![CDATA[SAM]]></given-names>
</name>
<name>
<surname><![CDATA[Roberts]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Carlier]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Verstraete]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
<name>
<surname><![CDATA[Stove]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[De Waele]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Population pharmacokinetics of continuous infusion of piperacillin in critically ill patients]]></article-title>
<source><![CDATA[Int J Antimicrob Agents]]></source>
<year>2018</year>
<volume>51</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>594-600</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Frippiat]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Musuamba]]></surname>
<given-names><![CDATA[FT]]></given-names>
</name>
<name>
<surname><![CDATA[Seidel]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Albert]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Denooz]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Charlier]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Modelled target attainment after meropenem infusion in patients with severe nosocomial pneumonia: The PROMESSE study]]></article-title>
<source><![CDATA[J Antimicrobial Chemother]]></source>
<year>2015</year>
<volume>70</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>207-16</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Florkowski]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Chew-Harris]]></surname>
<given-names><![CDATA[JSC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Methods of Estimating GFR - Different equations including CKD-EPI]]></article-title>
<source><![CDATA[Clin Biochem Rev]]></source>
<year>2011</year>
<volume>32</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>75-9</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="book">
<collab>IBM Watson Health</collab>
<source><![CDATA[IBM Micromedex® web applications access]]></source>
<year>1970</year>
<publisher-loc><![CDATA[Greenwood Village, Colorado, USA ]]></publisher-loc>
<publisher-name><![CDATA[Copyright IBM Corporation]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rigo-Bonnin]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ribera]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Arbiol-Roca]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cobo-Sacristán]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Padullés]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Murillo]]></surname>
<given-names><![CDATA[Ò]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Development and validation of a measurement procedure based on ultra-high performance liquid chromatography-tandem mass spectrometry for simultaneous measurement of &#946;-lactam antibiotic concentration in human plasma]]></article-title>
<source><![CDATA[Clin Chim Acta]]></source>
<year>2017</year>
<volume>468</volume>
<page-range>215-24</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="book">
<collab>Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)</collab>
<source><![CDATA[Centro de información online de medicamentos (CIMA) de la AEMPS]]></source>
<year>1997</year>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Ministerio de Sanidad, Servicios Sociales e Igualdad]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="book">
<collab>European Society of Clinical Microbiology and Infectious Diseases (ESCMID)</collab>
<source><![CDATA[Clinical breakpoints-bacteria]]></source>
<year>1983</year>
<edition>v 9.0</edition>
<publisher-loc><![CDATA[Sweden ]]></publisher-loc>
<publisher-name><![CDATA[The European Commitee on Antimicrobial Susceptibility Testing (EUCAST)]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abdul-Aziz]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[Sulaiman]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Mat-Nor]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Rai]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Wong]]></surname>
<given-names><![CDATA[KK]]></given-names>
</name>
<name>
<surname><![CDATA[Hasan]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis]]></article-title>
<source><![CDATA[Intensive Care Med]]></source>
<year>2016</year>
<volume>42</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1535-45</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abdul-Aziz]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[Lipman]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Akova]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bassetti]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Waele]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Dimopoulos]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patient (DALI) cohort]]></article-title>
<source><![CDATA[J Antimicrob Chemother]]></source>
<year>2016</year>
<volume>71</volume>
<page-range>196-207</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mouton]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
<name>
<surname><![CDATA[Hollander]]></surname>
<given-names><![CDATA[JG den]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model]]></article-title>
<source><![CDATA[Antimicrob Agents Chemother]]></source>
<year>1994</year>
<volume>38</volume>
<page-range>931-6</page-range></nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aardema]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Nannan Panday]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Wessels]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hateren]]></surname>
<given-names><![CDATA[K van]]></given-names>
</name>
<name>
<surname><![CDATA[Dieperink]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Kosterink]]></surname>
<given-names><![CDATA[JGW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Target attainment with continuous dosing of piperacillin/tazobactam in critical illness: a prospective observational study]]></article-title>
<source><![CDATA[Int J Antimicrob Agents]]></source>
<year>2017</year>
<volume>50</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>68-73</page-range></nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carrié]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Petit]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[d&#8217;Houdain]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Sauvage]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Cottenceau]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Lafitte]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Association between augmented renal clearance, antibiotic exposure and clinical outcome in critically ill septic patients receiving high doses of &#946;-lactams administered by continuous infusion: a prospective observational study]]></article-title>
<source><![CDATA[Int J Antimicrob Agents]]></source>
<year>2018</year>
<volume>51</volume>
<numero>39</numero>
<issue>39</issue>
<page-range>443-9</page-range></nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wong]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Brinkman]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Benefield]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Carlier]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[De Waele]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[El Helali]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An international, multicentre survey of &#946;-lactam antibiotic therapeutic drug monitoring practice in intensive care units]]></article-title>
<source><![CDATA[J Antimicrob Chemother]]></source>
<year>2014</year>
<volume>69</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1416-23</page-range></nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wong]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Briscoe]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Adnan]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[McWhinney]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Ungerer]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lipman]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Protein binding of &#946;-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations?]]></article-title>
<source><![CDATA[Antimicrob Agents Chemother]]></source>
<year>2013</year>
<volume>57</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>6165-70</page-range></nlm-citation>
</ref>
<ref id="B27">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ulldemolins]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Roberts]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Rello]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Paterson]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<name>
<surname><![CDATA[Lipman]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients]]></article-title>
<source><![CDATA[Clin Pharmacokinet]]></source>
<year>2011</year>
<volume>50</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>99-110</page-range></nlm-citation>
</ref>
<ref id="B28">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stevens]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Coresh]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Greene]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Levey]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Assessing kidney function: measured and estimated glomerular filtration rate]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2006</year>
<volume>354</volume>
<numero>23</numero>
<issue>23</issue>
<page-range>2473-83</page-range></nlm-citation>
</ref>
<ref id="B29">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Blondiaux]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Wallet]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Favory]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Onimus]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Nseir]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Courcol]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Daily serum piperacillin monitoring is advisable in critically ill patients]]></article-title>
<source><![CDATA[Int J Antimicrob Agents]]></source>
<year>2010</year>
<volume>35</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>500-3</page-range></nlm-citation>
</ref>
<ref id="B30">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Roberts]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Kirkpatrick]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Roberts]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Robertson]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
<name>
<surname><![CDATA[Dalley]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Lipman]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution]]></article-title>
<source><![CDATA[J Antimicrob Chemother]]></source>
<year>2009</year>
<volume>64</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>142-50</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
